The evaluation of herpes simplex virus (HSV) vaccine efficacy will require methods to detect asymptomatic acquisition of HSV infection and to assess the risk of recurrences in these patients. HSV-infected vaccinees should develop antibodies to HSV polypeptides not included in subunit vaccines. Sera from 57 HSV glycoprotein-vaccinated guinea pigs that had asymptomatic initial infections after genital HSV type 2 challenge were collected after vaccination but before HSV challenge and again 30 days after HSV challenge to determine the antibody response to HSV polypeptides. Antibodies to nonvaccine HSV polypeptides were detected in sera collected after viral challenge from 32 (56%) of these 57 animals. Twenty-six (81%) of the 32 animals with detectable antibody developed recurrent disease; however, recurrences also developed in 11 (44%) of the remaining 25 that did not show detectable antibody to nonvaccine HSV polypeptides. The magnitude of vaginal viral shedding during the initial disease period following challenge was significantly lower in animals that did not develop antibody to nonvaccine polypeptides compared with those that did develop antibody (area under the viral shedding curve, 5.2 ± 3.2 versus 18.1 ± 5.8; P < 0.0001). These data suggest that detection of antibody to nonvaccine HSV polypeptides will identify the majority (70%) of initially asymptomatic vaccinees that develop recurrent disease but that latency can be established even with markedly reduced levels of viral replication that did not induce a detectable antibody response.
The evaluation of herpes simplex virus (HSV) vaccine efficacy will require methods to detect asymptomatic acquisition of HSV infection and to assess the risk of recurrences in these patients. HSV-infected vaccinees should develop antibodies to HSV polypeptides not included in subunit vaccines. Sera from 57 HSV glycoprotein-vaccinated guinea pigs that had asymptomatic initial infections after genital HSV type 2 challenge were collected after vaccination but before HSV challenge and again 30 days after HSV challenge to determine the antibody response to HSV polypeptides. Antibodies to nonvaccine HSV polypeptides were detected in sera collected after viral challenge from 32 (56%) of these 57 animals. Twenty-six (81%) of the 32 animals with detectable antibody developed recurrent disease; however, recurrences also developed in 11 (44%) of the remaining 25 that did not show detectable antibody to nonvaccine HSV polypeptides. The magnitude of vaginal viral shedding during the initial disease period following challenge was significantly lower in animals that did not develop antibody to nonvaccine polypeptides compared with those that did develop antibody (area under the viral shedding curve, 5.2 ± 3.2 versus 18.1 ± 5.8; P < 0.0001). These data suggest that detection of antibody to nonvaccine HSV polypeptides will identify the majority (70%) of initially asymptomatic vaccinees that develop recurrent disease but that latency can be established even with markedly reduced levels of viral replication that did not induce a detectable antibody response.
Several subunit herpes simplex virus (HSV) glycoprotein vaccines have shown efficacy in animal studies (4, 5, 12, 14, 21) , and human clinical trials have been initiated (16) . Vaccine efficacy has classically been evaluated by the ability to prevent acute symptomatic disease. However, an effective HSV vaccine should not only modify acute infection, but also prevent or reduce the establishment of latency to prevent or reduce subsequent recurrent disease. Latent infections can be established in asymptomatically infected individuals or in those with atypical or unrecognized symptoms (11, 13, 17) . Initially asymptomatic patients can develop symptomatic recurrent diseases (6) and serve as a source of infection for their sexual partners (15, 19) or, in the case of pregnant women, their newborn infants (18) .
In our initial animal trials, candidate HSV glycoprotein vaccines reduced the severity of initial disease, many animals developing initially asymptomatic infection. Vaccination also reduced but did not eliminate recurrent disease even in initially asymptomatic animals (21; L. R. Stanberry et al., J. Gen. Virol., in press). Therefore, it appears that evaluation of HSV vaccine efficacy will require methods to detect asymptomatic acquisition of HSV infection to allow assessment of the risk of recurrences.
Infected vaccinees should produce antibodies to HSV polypeptides not included in the subunit vaccine. We have recently reported that animals immunized with HSV glycoproteins that developed symptomatic infection after HSV type 2 (HSV-2) vaginal inoculation reliably produced antibody to the nonglycosylated ICP-35 group of HSV proteins and that this served as a useful prognostic indicator to identify animals that developed more severe recurrent dis-* Corresponding author. ease (9) . Rises in neither neutralizing nor enzyme-linked immunosorbent assay titers identified even symptomatic animals. The sensitivity for identifying initially asymptomatic animals that developed recurrent disease, using detection of ICP-35 antibody, was only 47%, however. In this report, we have extended our evaluation from the 35 animals that had asymptomatic initial infections after genital HSV-2 challenge reported previously (9) and have used other procedures to identify antibody to HSV polypeptides (2, 3) as a means to predict animals that develop recurrent disease.
MATERIALS AND METHODS
HSV vaccines. The subunit glycoprotein vaccines and their administration have been described previously (20) (21) (22) 14-day interval after inoculation, the period when unvaccinated animals develop and recover from their initial lesions (7, 23) .
Sera were collected 30 days after the second immunization, immediately prior to intravaginal HSV-2 inoculation, and again 30 days after viral challenge. We have shown previously (7) that HSV-2 antibody response peaks in HSV-2-infected guinea pigs at about 30 days after viral inoculation and that antibody to HSV polypeptide ICP-35 is present in all animals at this time. Sera were stored frozen at -70°C until use. Of the 59 serum pairs from initially asymptomatic animals, 57 were available for analysis by immunoblotting.
Evaluation of initial and recurrent disease. All animals were evaluated daily from days 1 through 60 for genital lesions (7, 23) , recurrent disease occurring from days 15 to 60 (24) . The titer of virus in the vaginal vault was determined from daily vaginal swab samples obtained on days 1 to 7 (18) . Clinical recurrences are reported as both lesion days (defined as total number of days with any lesion) and recurrent episodes (defined as a new lesion appearing after a lesionfree day) (8) .
Immunoblot assay. The immunoblot procedures were performed with '25I-labeled protein A (procedure A) (9) gave discrepant results, both identified as containing antibody to nonvaccine polypeptides only when reacted in the system that used peroxidase-conjugated anti-guinea pig IgG. Seven sera gave an indeterminate result in this assay, only one of which was reactive to nonvaccine polypeptides when probed with '25I-labeled protein A. A result was categorized as indeterminant when a weak reaction to only a single nonvaccine HSV polypeptide (usually the 40-kilodalton polypeptide of the ICP-35 group) was observed. By combining the results from both assays, 31 animals developed antibody to nonvaccine polypeptides, while 7 additional animals had some evidence of antibody production.
We next used radioimmunoprecipitation to examine the antibody response in four serum pairs from animals with recurrences that were not identified by either immunoblotting assay and two sera that had given discrepant results in the two peptides was identified in the postchallenge sera from one of the four sera not identified by immunoblotting and in both sera that had given discrepant results. The sera that reacted to nonvaccine polypeptides by only this assay were obtained from one of two animals with an area under the log viral titer per day curve of >12 (see below) that had not developed antibody to nonvaccine polypeptides by Western blot analysis. With the results for all three assays, a total of 32 of the 59 animals had detectable antibody to nonvaccine HSV polypeptides.
The magnitude of acute vaginal viral replication appeared to determine which animals responded to nonvaccine HSV polypeptides. Antibody to nonvaccine polypeptides was detected in 27 of 28 animals with an area under the log viral shedding curve of .12 (including the animal positive only by immunoprecipitation), while only 4 of 29 with lesser virusshedding values developed detectable antibody. Vaginal viral replication was significantly greater (P < 0.0001) in animals that developed antibody than in those that did not (Table 3) .
Recurrent disease in initially asymptomatic animals. If all vaccinated animals that developed a latent HSV infection produced detectable antibody to nonvaccine polypeptides after viral challenge, then recurrences should only have developed in animals with antibody to nonvaccine polypeptides. We found that recurrences developed in 26 of 32 (81%) animals that produced antibodies to nonvaccine HSV polypeptides but also in 11 of 25 (44%) animals that did not develop such antibodies (P < 0.005; Table 2 ). Both the number of recurrent episodes (P < 0.005) and the number of recurrent lesion days (P < 0.001) were significantly greater in animals with detectable antibodies to nonvaccine HSV polypeptides ( Table 2) .
All of the animals that developed recurrent disease in the absence of detectable antibodies to nonvaccine polypeptides had areas under the log viral shedding curve of <12. The magnitude of vaginal viral replication was not significantly different in these animals compared with animals that developed neither recurrences nor antibody to nonvaccine poly- , albeit at reduced rates. Determination of serologic markers to identify those vaccinees that establish a latent viral infection after HSV exposure which could later reactivate is therefore needed. In these studies, we have sought to identify such a marker, reasoning that immunoblotting should allow detection of antibodies to HSV polypeptides not included in the vaccine but which might be expected to be produced after HSV infection. Such markers have been used in human vaccine studies (2) . However, the sensitivity of these markers could not be determined because of the uncertainties of postvaccination exposure to HSV in human subjects.
Recurrent disease (a clinical manifestation of latent infection) developed from days 15 to 60 in 37 of the 57 vaccinated animals that had not developed lesions during the acute infection period. Most guinea pigs latently infected with HSV develop recurrent disease during this period of observation (24; our unpublished observation). Of the 37 animals, 25 (68%) developed detectable antibody to nonvaccine polypeptides when evaluated by immunoblotting and an additional animal was identified when evaluated by immunoprecipitation (70%). Furthermore, one of the immunoblotting procedures identified another four of these animals as having a partial response to nonvaccine polypeptides which was classified as indeterminate. Thus, although these procedures identified the majority of asymptomatically acquired latent infections that led to recurrences, at least seven animals developed recurrences in spite of developing no evidence of antibody to nonvaccine polypeptides.
As observed previously (9) , the magnitude of vaginal viral shedding determined which animals developed detectable antibody to nonvaccine HSV polypeptides. Presumably, a minimal antigenic mass is required to elicit a detectable antibody response. Of the 11 animals with recurrent disease that did not develop detectable nonvaccine antibodies, all had an area under the viral shedding curve of <12 (mean, 6.3 ± 2.6). Thus, it appeared that virus entered neural tissues early and established a latent infection even though local viral replication was low. Whether levels of antibody that were below the sensitivities of our assays were produced in these animals is unknown.
The most commonly detected antibody to nonvaccine HSV polypeptides was anti-ICP-35 antibody (9) . This antibody was detected in all animals that developed antibodies to nonvaccine polypeptides in both immunoblotting assays. It is possible that an enzyme-linked immunosorbent assay directed at this antigen would be more sensitive than the immunoblotting assays reported here, as has proven to be the case in detection of anti-glycoprotein D antibody (8) .
Detection of antibody to nonvaccine HSV polypeptides, 
